ArticleEuropean journal of radiology2026
Use of Artificial Intelligence in prostate MRI: A rapid scoping review highlighting limited evidence in screening context.
Article in European journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveArtificial Intelligence (AI) is seen as a potential solution to alleviate workforce demands arising from growing use of magnetic resonance imaging (MRI) in prostate cancer (PCa) screening. We aimed to synthesize the evidence on use of AI in prostate MRI readings in asymptomatic men in PCa screening settings.
methodsWe conducted a rapid scoping review following PRISMA-ScR guidelines and Cochrane rapid review methods performing the systematic search of major databases supplemented by grey literature search with no restrictions in study design and time-duration. We considered various aspects of utilization of AI in MRI interpretations and biopsy indications in the screening setting. Anticipating limited evidence on AI implementation in screening settings, we extended the review from 'what is known' to discussion on 'key considerations for expected expansion'. KEY FINDINGS AND LIMITATIONS: We identified 284 records with 47 studies assessed for eligibility and two studied met the inclusion criteria. Both evaluated commercially available ProstateAI software tool to interpret prostate MRI. Agreement between deep learning-based algorithm of AI and expert radiologist ranged from poor to moderate (kappa 0.17-0.42). AI demonstrated high tendency of over-detection and low specificity, leading to discordance with expert radiologists. CONCLUSIONS AND CLINICAL IMPLICATIONS: Current evidence on use of AI in prostate MRI interpretation is limited, but this review highlights several important directions for future research and implementation. Generating robust evidence base in the coming years will be crucial to ensure that AI integration enhances the effectiveness and acceptability of future prostate cancer screening programs. PATIENT SUMMARY: In this study, we examined whether Artificial Intelligence (AI) tools can accurately read prostate MRI scans of apparently healthy men for early detection of prostate cancer. We found that deploying current AI tools that are trained and tested in hospital referred patients may not be optimal to read MRI performed in asymptomatic men. We conclude that AI needs much more training and testing in real screening populations before it can be safely used in prostate cancer screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.